INO — INOVIO PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1055726 ·
Last close
$1.63
Market Cap
$305.31M
52W High
$2.72
52W Low
$0.56
ADV30
19,908,862
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 298,901 | — | -19,524,930 | -49,204,789 | 60,136,243 | 46,962,549 | 94,059,215 |
| Jun 2026 | 0 | — | -18,624,522 | -6,012,458 | 49,389,494 | 31,526,164 | 45,018,411 |
| Mar 2026 | 0 | — | -21,949,993 | -19,682,798 | 49,777,142 | 26,271,650 | 43,709,260 |
| Dec 2025 | 0 | — | -17,476,601 | 3,764,880 | 74,310,035 | 44,273,319 | 50,213,759 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-74,283,716
Investing CF
$12,447,856
Financing CF
$72,230,989
CapEx
$-285,698
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.72
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,890,065,208
Inventory
—
Receivables
$450
ST Investments
$1,398,734
EBIT TTM
$-56,334,565
Pretax Income TTM
$-71,135,165
Interest Exp TTM
$0
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$298,901
EBITDA
$-76,274,936
Free Cash Flow
$-20,820,800
Enterprise Value
$226,769,296
Total Cash
$48,361,284
Total Debt
$7,281,738
Shares Out
187,306,884
Trailing EPS
$-0.59
Book Value
$-0.18
ROE
-409.9%
ROA
-74.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 65,343 | -86,822,104 | -84,945,901 | 74,310,035 | 50,213,759 | 24,096,276 | -88,629,430 |
| Dec 2024 | 217,756 | -112,398,922 | -107,254,126 | 113,197,206 | 44,693,411 | 68,503,795 | -104,076,553 |
| Dec 2023 | 832,010 | -133,426,657 | -135,117,352 | 170,951,423 | 53,602,294 | 117,349,129 | -124,365,551 |
| Dec 2022 | 10,262,268 | -267,573,520 | -279,818,065 | 348,533,302 | 126,170,546 | 222,362,756 | -216,215,421 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-67,427,048
OpCashFlow TTM
—
Assets (Latest)
$49,389,494
Forward EPS
$-0.03
Max Pain — expiry 2026-12-18
max pain strike: $1.00 · spot: $1.69 · call oi: 14,274 · put oi: 790
Expected Move to 2026-12-18:
±$0.48
(28.11%) —
implied range
$1.22 –
$2.17
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LRMR | Larimar Therapeutics, Inc. | $310.61M | $2.99 | — |
| ALT | Altimmune, Inc. | $297.72M | $1.53 | — |
| GALT | GALECTIN THERAPEUTICS INC | $293.47M | $2.91 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $318.00M | $3.96 | — |
| EVMN | Evommune, Inc. | $290.28M | $7.02 | — |
News headlines (Yahoo Finance, 1h cache)
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis
2026-11-18 13:05 · Yahoo
Inovio Pharmaceuticals (INO) Stock Gets Fair Value Boost After VOCERYQ Approval
2026-11-18 03:12 · Yahoo
Inovio Pharmaceuticals Inc (INO) (Q3 2026) Earnings Call Highlights: FDA Approval, Commercial ...
2026-11-12 11:03 · Yahoo
Inovio Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
INOVIO to Participate in Upcoming Investor Conferences
2026-11-11 13:05 · Yahoo
Inovio (INO) Q3 2026 Earnings Call Transcript
2026-11-11 04:00 · Yahoo
Inovio: Q3 Earnings Snapshot
2026-11-10 21:25 · Yahoo
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-10 21:05 · Yahoo
Inovio stock tumbles 25% on $75M share offering
2026-11-06 16:36 · Yahoo
INOVIO Announces Pricing of Approximately $75 Million Public Offering
2026-11-06 04:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.